AstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia (MDL), and expects to write off at least $100 million from its profits in Q4 as a ...
Contributed by John F. Brady; received November 21, 2022; accepted March 24, 2023; reviewed by Hartmut Loewen, M. Cristina Marchetti, and Ignacio Pagonabarraga This contribution is part of the special ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback